Introduction: Hypertension is a global health challenge frequently exacerbated by poor adherence to pharmacological and restrictive dietary interventions. Low-Sodium Salt Substitutes (LSSS) offer a palatable alternative to traditional salt restriction. This case series evaluates the clinical impact of LSSS on blood pressure (BP) and body weight in a cohort of hypertensive patients. Methods: A retrospective analysis was conducted on five adult patients (n=5) with essential hypertension managed in an outpatient setting. Participants were transitioned from standard table salt to LSSS as an adjuvant to optimized antihypertensive pharmacotherapy. Longitudinal data on BP, body weight, and renal parameters (serum electrolytes, urea, and creatinine) were collected over six bi-weekly clinical visits. Results: The implementation of LSSS resulted in a mean systolic BP reduction of 16 mmHg and a mean weight loss of 6.7 kg over eight weeks. Significant improvements in renal clearance were observed, with mean serum creatinine decreasing from 1.48 mg/dL to 1.04 mg/dL. Serum potassium remained stable (mean: 3.98 mmol/L), demonstrating the safety of the intervention even in high-risk profiles, including a post-nephrectomy patient. Conclusion: LSSS is a highly effective, low-cost intervention that synergizes with pharmacotherapy to achieve rapid BP stabilization and sustained weight loss. These findings support the integration of salt substitutes into primary care protocols to improve therapeutic adherence and cardiovascular outcomes.